Half of American use fitness trackers on daily basis

Over half of Americans (51 percent) report using a wearable fitness tracker at least once a day, according to a report conducted by Researchscape International.

Fitness wearables are an increasingly common method to collect patient data, and this report aimed to outline how patients use their wearables. The report contains data collected from 1,041 consumers from November 2017.

Findings included:

  • 40 percent have used a wearable device for tracking their health, exercise or sports performance.
  • The main uses for trackers include measuring steps (39 percent), calories burned (36 percent), heartbeat (31 percent), distance (28 percent) and sleep quality (25 percent).
  • 76 percent would review wearable devices as very or extremely valuable if they could automatically calculate calories consumed. Similarly, respondents believed the same if hydration level (82 percent) and stress level (80 percent) were also included.
  • Ease of product use and mobile app use were the most appreciated aspects by 45 percent of respondents, followed by device design (37 percent) and price (35 percent).

"Active people concerned about health, weight and well-being want to be able to monitor their status and progress," said Artem Shipitsyn, CEO and co-founder of Healbe. "Having technology that can automatically monitor, measure and report on multiple health factors makes it easy to do so and significantly easier to recognize bad habits and integrate healthier habits into a daily routine. Fitness coaches and nutritionists can also track how their recommendations are implemented, tailor their programs in real time and achieve their clients' goals more efficiently."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.